Boston Scientific reports significant growth in endoscopy business – grows 54 percent

In Q2, medtech firm Boston Scientific sold significantly more endoscopy products, which is the core business area of Danish company Ambu. The US giant is upgrading its guidance for the whole year.

Photo: Ambu PR

Medtech giant Boston Scientific has had the wind in its sails during the second quarter of 2021.

In Q2, it delivered a USD 3.08bn revenue, up against the predicted USD 2.94bn, and it had a 52.4 percent organic growth compared to the same time period last year.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs